Why Sanofi Is a Buy

All week, Cramer has been highlighting big pharma stocks that are poised to pop in the year to come. But the “Mad Money” host saved his fave stock for last, namely, Sanofi-Aventis .

Sanofi is the world’s largest drug company with a stock that sports a 4.8 percent dividend yield. The stock has run up by 16 percent last year, if you had reinvested dividends, but Cramer thinks it could still go higher.

Cramer likes Sanofi because three of its biggest drugs are going generic this year, but the company saw the dangers coming and took steps to make sure it never happens again. He hands it to the company’s management, who he praised for their strategic thinking and leadership.

Going forward, the company is investing in high growth platforms that are protected by more than just a patent, such as vaccines where barriers to entry are high, diabetes and generics. In doing so, the company hopes to build brand loyalty.
Cramer thinks Sanofi is a buy, buy, buy.

When this story was published, Cramer's charitable trust owned Sanofi.

Call Cramer: 1-800-743-CNBC

Questions for Cramer? madmoney@cnbc.com

Questions, comments, suggestions for the Mad Money website? madcap@cnbc.com

Contact Mad Money

  • Showtimes

    Monday - Friday 6p ET
    Saturday 8a, 1p, 7p SYD
    Sunday 12a, 1a, 8a, 7p SYD
    New Zealand
    Saturday 10a, 3p, 9p NZ
    Sunday 2a, 3a, 10a, 9p NZ
  • Jim Cramer is host of CNBC's "Mad Money" and co-anchor of the 9 a.m. ET hour of CNBC's "Squawk on the Street."

Mad Money Features

  • Grab the latest CNBC gear from the NBCUniversal Store!

  • Get a behind-the-scenes look at how Cramer formulates his investment advice. "Inside the Madness" is a column, which features e-mails and more with Cramer and his researcher Nicole Urken.

  • You’ve always wanted to hit the “Hallelujah!” button. Here’s your chance.

Mad Money Moments

Cramer's New Book